Comparison of the immunogenicity and safety of Euvichol-Plus with Shanchol in healthy Indian adults and children: an open-label, randomised, multicentre, non-inferiority, parallel-group, phase 3 trial [0.03%]
Euvichol-Plus和Shanchol疫苗在印度健康成人和儿童中的免疫原性和安全性比较：一项开放标签、随机、多中心、非劣效性平行分组三期试验
Sanket Shah,Ranjan Kumar Nandy,Shaily S Sethi et al.
Sanket Shah et al.
Background: Considering the cholera menace in India and to seek licensure of the oral cholera vaccine (OCV), Euvichol-Plus, we conducted a clinical trial to compare the immunogenicity and safety of Euvichol-Plus with Shan...
Cytokine profile, neutralisation potential and viral replication dynamics in sera of chikungunya patients in India: a cross-sectional study [0.03%]
印度恰坤加热病患者血清细胞因子谱、中和潜力及病毒复制动力学：横断面研究
Naren Babu,Shakuntala Mahilkar,Anup Jayaram et al.
Naren Babu et al.
Background: Chikungunya disease (CHIKD) is a threat to global health, as it impairs the quality of life of an infected individual ranging from months to years. A systematic evaluation of the serological, virological, and ...
Clinical characteristics and novel mutations of omicron subvariant XBB in Tamil Nadu, India - a cohort study [0.03%]
印度泰米尔纳德邦新冠病毒奥密克戎XBB亚型株的临床特征及新型突变——队列研究
Sivaprakasam T Selvavinayagam,Sree J Karishma,Kannan Hemashree et al.
Sivaprakasam T Selvavinayagam et al.
Background: Despite the continued vaccination efforts, there had been a surge in breakthrough infections, and the emergence of the B.1.1.529 omicron variant of SARS-CoV-2 in India. There is a paucity of information global...
Soham D Bhaduri
Soham D Bhaduri
Rabies control in high-burden countries: role of universal pre-exposure immunization [0.03%]
高疾病负担国家狂犬病控制：普遍预防接种的作用
Lonika Lodha,Ashwini Manoor Ananda,Reeta S Mani
Lonika Lodha
Rabies is a fatal zoonotic encephalitis that is responsible for approximately 59,000 deaths worldwide every year. A significant portion of these deaths, about one-third, occur in India alone. In order to meet the World Health Organization's...
The Lancet Regional Health-Southeast Asia
The Lancet Regional Health-Southeast Asia
Inflammatory bowel disease (IBD) in rural and urban India: results from community colonoscopic evaluation of more than 30,000 symptomatic patients [0.03%]
印度农村和城市地区的炎症性肠病(IBD)：对3万余例症状患者的社区结肠镜检查结果
Rupa Banerjee,Partha Pal,Rajendra Patel et al.
Rupa Banerjee et al.
Background: Traditionally, infectious diarrhoea has been the major cause of lower GI symptoms across the developing world. Increasing urbanization has been implicated for the rising IBD cases despite very limited data in ...
Finishing the task of eliminating neglected tropical diseases (NTDs) in WHO South-East Asia Region: promises kept, challenges, and the way forward [0.03%]
消除热带病，实现世卫组织东南亚区域2030年目标：已兑现的承诺、面临的挑战及解决办法
Aya Yajima,Zaw Lin,Ahmed Jamsheed Mohamed et al.
Aya Yajima et al.
Globally 20 Neglected tropical diseases (NTDs) are prioritized by World Health Organization (WHO), of which 15 are present in the South-East Asia Region (SEAR) with all 11 countries being affected. As the region bears 54% of the global burd...
The Lancet Regional Health-Southeast Asia
The Lancet Regional Health-Southeast Asia
Measles and rubella elimination: protecting children through immunization in South-East Asia Region (SEAR) [0.03%]
消灭麻疹和风疹保护东南亚地区儿童接种疫苗
Sunil Bahl,Sudhir Khanal,Lucky Sangal et al.
Sunil Bahl et al.
The South-East Asia Region (SEAR) adopted the goal of "measles and rubella elimination by 2023". The goal was revised in 2019 to 'measles and rubella elimination by 2023' The strategies adopted to reach the goal included achieving ≥95% cov...